BETA

13 Amendments of Nicola DANTI related to 2020/2071(INI)

Amendment 17 #
Draft opinion
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can poses a risk when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health which includes guidelines on the diversification of pharmaceutical supply chains;
2020/05/18
Committee: INTA
Amendment 25 #
Draft opinion
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of well-balanced IP rights in free trade agreements (FTAs) and at the WTO is crucial toshould serve the development of new medicines and treatments; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstances; stresses that public health crises should constitute legitimate grounds for activating such flexibilities; and notes that developing countries may need to rely on these flexibilities in order to respond appropriately to the COVID-19 crisis;
2020/05/18
Committee: INTA
Amendment 28 #
Draft opinion
Paragraph 1
1. Calls on the Member States to enhance their cooperation in order to improve the medical supply and distribution chain through better visibility and efficient monitoring, particularly on cross-especially on "green lane" border croutessings, and to establish corridors where medical supplies have priority of deliverycalls on Member States to implement the Green Lanes under the Guidelines for border management measures to protect health and ensure the availability of goods and essential services without unnecessary restrictions across borders;
2020/05/19
Committee: TRAN
Amendment 34 #
Draft opinion
Paragraph 1 a (new)
1 a. Highlights that the air freight is a crucial part of the pharmaceutical supply chain; and therefore calls on the Commission and the Member States to create dedicated hubs in the Union to build receiving points of air freight of medicines, active pharmaceutical ingredients and medical equipment insufficient capacity in order to cover needs of the supply chain as well as creating open routes between the Union and third countries for these essential goods; calls on the Member States to encourage cargo and express airlines to apply reasonable shipping rates for medical and emergency supplies;
2020/05/19
Committee: TRAN
Amendment 42 #
Draft opinion
Paragraph 4
4. Emphasises that a broad network of FTAs together with a fully functioning multilateral trading system with the World Trade Organisation and an operational Appellate Body at its core constitute the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and regulatory standards converge globally;
2020/05/18
Committee: INTA
Amendment 42 #
Draft opinion
Paragraph 3
3. Calls on the Member States to adopt strategic plans to upgrade their existing infrastructure for an efficient supply of medicines; deems it necessary to remove bottlenecks, boost intermodality (while favouring the shift to rail), finance the main hubs (ports, airports and intermodal platforms), and enhance the delivery of various types of goods, including dangerous goods crucial for the production of the chemical and pharmaceutical industry, in close cooperation with the Commission and with all interested stakeholders involved, to take coordinated measures and to adopt strategic plans to upgrade their existing infrastructure for an efficient supply of medicines; including by foreseeing the creation of European common strategic reserves, building on rescEU stockpile's initiative; deems it necessary to remove bottlenecks, boost intermodality, finance the main hubs, and enhance the delivery of various types of goods, including dangerous goods crucial for the production of the chemical and pharmaceutical industry; calls on the Member States to ensure that medical facilities and medical staff in place are reinforced, in order tobe able to carry out the increasing traffic volumes while restrictions are lifted;
2020/05/19
Committee: TRAN
Amendment 49 #
Draft opinion
Paragraph 3 a (new)
3 a. Welcomes the contribution of the armed forces of Member States to the supply chain of medicines and protective equipment during the COVID-19 outbreak; therefore, calls on the Commission and the Member States, in close cooperation with the European Medicines Agency, to enhance the cooperation for the use of national military resources, where available and necessary, to assist the supply chain of medicines and protective equipments among Member States, as part of PESCO cooperation framework;
2020/05/19
Committee: TRAN
Amendment 50 #
Draft opinion
Paragraph 5
5. Strongly encourages all countries to join the WTO’s Pharmaceutical Tariff Elimination Agreement; callurges for its scope to be extended to all pharmaceutical and medicinal products; stresses that medical products should at all times be exempted from retaliation in trade disputes;
2020/05/18
Committee: INTA
Amendment 54 #
Draft opinion
Paragraph 4
4. Highlights the importance of IT systems in facilitating the exchange of information between the various actors involved in the transport logistics chain, including the customs authorities, with a view to optimising the distribution of medicines in the Member States and planning supply times more efficiently; calls on the Commission to carefully evaluate the benefits as well as the risks that artificial intelligence may bring for the fast and reliable delivery of medical supplies;
2020/05/19
Committee: TRAN
Amendment 56 #
Draft opinion
Paragraph 5
5. Notes the importance of guaranteeing high safety standards for both transport infrastructure, for transport workers and employees, making it possible to manage significant volumes in the supply chain without disruptions or posing risks to healthf the supply chains and without prejudice for the competent authorities to take proportionate and adapted measures to minimise the risks of contagion; furthermore, notes the importance of the careful management of the ambient and cold-chain warehouse capacity in inbound and outbound transport infrastructure and, if necessary, the introduction of emergency or self- certification of additional capacity of pharmaceutical products;
2020/05/19
Committee: TRAN
Amendment 57 #
Draft opinion
Paragraph 6
6. Underlines that a complete repatriation of medical supply chains is not possible in a global economy nor is it desirable; urges the Commission and the Member States to work with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionist measures during health crises; calls on the Commission to explore the creation of a common European strategic reserve of medicines, building on the rescEU stockpile initiative.
2020/05/18
Committee: INTA
Amendment 64 #
Draft opinion
Paragraph 6
6. Stresses the importance of catering to specific transport needs at local and regional levels, particularly in rural, mountain, sparsely populated and insular areas that are more difficult to access and involve higher delivery costs; notes that there are new automated delivery tools, such as via drones, available on the market that could help operators to access these areas; e importance of their inclusion to the digital transition and also the need to accelerating the uptake of new solutions adapted to the needs of these areas, allowing connectivity, accessibility and affordability; stresses that the access to medicines in these areas should not in any case be hampered;
2020/05/19
Committee: TRAN
Amendment 74 #
Draft opinion
Paragraph 7
7. Notes that the COVID-19 outbreak has laid bare the weaknessighlighted the importance of cooperation and solidarity between Member States ofin the Europeanfield of medical production systemand supply, highlighting the importance of delivering medicines swiftly in urgent and exceptional circumstances that could arise in the future.
2020/05/19
Committee: TRAN